Table 1.
A comparison of MOG-IgG CSF+/serum– patient characteristics between this study and the Oxford cohort from Jurynczyk et al
| Clinical characteristic | MOG-IgG CSF+/serum– (n=2) |
Jurynczyk et al
(n=75) |
| Age | 24, 69 | 29±16.5 (Mean±SD) |
| Female (%) | 100 | 56 |
| CSF MOG-IgG CBA score | 1, 4 | NA |
| Serum MOG-IgG CBA score | 0.75, 0.75 | NA |
| Time since onset (years) | 3, 4 | NA |
| Onset attack (%) | ||
| Unilateral ON | 0 | 25 |
| Bilateral ON | 0 | 27 |
| Transverse myelitis | 100 | 20 |
| ADEM | 0 | 20 |
| Simultaneous ON and TM | 0 | 8 |
| Disease course (%) | ||
| Monophasic | 100 | 41 |
| Relapsing | 0 | 59 |
| Endpoints (%) | ||
| VA ≤6/36 | 0 | 16 |
| Limiting walking distance | 50 | 7 |
| Permanent bladder dysfunction | 50 | 28 |
| Catheterisation | 50 | 17 |
| Permanent bowel dysfunction | 50 | 20 |
ADEM, acute disseminated encephalomyelitis; CBA, cell-based assay; scored on a scale of 0 to 4; CSF, cerebrospinal fluid; MOG, myelin oligodendrocyte glycoprotein; NA, non-applicable; ON, optic neuritis; TM, transverse myelitis; VA, visual acuity.